title: How statins could be evaluated successfully in clinical trials for Alzheimer's disease?
abstract: Over the last decade, a large number of experimental observations have suggested a relationship between alterations in cholesterol homeostasis and Alzheimer's disease (AD). Moreover, epidemiological studies have pointed an association between statin treatment and a decrease in the risk of having AD. For these reasons, a large number of clinical trials have been carried out to determine whether the statins can prevent the progression of AD. However, these studies did not provide clear evidence for the therapeutic efficacy in AD. We consider that there are a number of explanations for this failure that may provide guidance for selecting and clinically developing statins with therapeutic efficacy in AD.
authors.affiliation: BioPharma Division, Neuron Bio, Parque Tecnológico de Ciencias de la Salud, Armilla, Granada, Spain. jburgos@neuronbio.com
authors.forename: Javier S
authors.initials: JS
authors.lastname: Burgos
authors.forename: Jesús
authors.initials: J
authors.lastname: Benavides
authors.forename: Patrice
authors.initials: P
authors.lastname: Douillet
authors.forename: Javier
authors.initials: J
authors.lastname: Velasco
authors.forename: Fernando
authors.initials: F
authors.lastname: Valdivieso
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D015415:Biomarkers / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol